Skip to content

Advertisement

  • Poster presentation
  • Open Access

Relapsing polychondritis: a pediatric series of ten patients

  • 1,
  • 5,
  • 3,
  • 1,
  • 2,
  • 2,
  • 2 and
  • 4
Pediatric Rheumatology20086 (Suppl 1) :P235

https://doi.org/10.1186/1546-0096-6-S1-P235

  • Published:

Keywords

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Vasculitis
  • Colchicine
  • Myelodysplastic Syndrome

Background

Relapsing polychondritis (RP) is a disease of unknown etiology and is characterized by cartilage inflammation. RP can be isolated or secondary to different diseases (vasculitis, myelodysplastic syndrome, rheumatoid arthritis or systemic lupus erythematosus). While the clinical picture of RP in adults is well known, RP in childhood remains poorly described.

Materials and methods

We retrospectively collected data from 10 patients followed in three French hospitals for relapsing polychondritis with an age at onset before 18 years.

Results

The mean age for the first symptoms was 8.6 ± 5.7 years (range 1.8–17). Symptoms included joint pain (10/10), ocular inflammation (4/9) and chondritis which concerned ears (10/10), nose (6/10) and larynx (5/10). Laboratory tests showed positive ANA in two patients (>1:160), absence of anticartilage antibodies, and a slight increase of the erythrocyte sedimentation rate in 5/9 patients (mean = 25 mm) Biopsy was performed in only two patients and showed perichondritis with eosinophilic and mononuclear infiltration for Pt2 while it was normal in Pt7. Treatment mainly consisted in NSAIDs (7/10), steroids (8/10), and methotrexate (6/10) and more rarely hydroxychloroquine (2/10), colchicine (1/10), dapsone (3/10), salazopyrine (2/10), azathioprine (1/10).

Pt 1 died of aortic insufficiency and others presented recurrent flares with chronic destroying chondritis.

Conclusion

Pediatric RP shares the main clinical features of its adult counterpart, even if secondary forms seem to be less frequent. Laboratory findings are nonspecific, and biopsies may be unnecessary. Evolution is marked by chronic destroying chondritis and could lead to fatal lesions despite immunosuppressive treatment.

Authors’ Affiliations

(1)
Hopital Femme Mère Enfant, Lyon, France
(2)
Hopital de la Pitié Salpetrière, Paris, France
(3)
Hopital d'enfant Armand Trousseau, Paris, France
(4)
Ospedale Pediatrico Meyer, Firenze, Italy
(5)
Hopital Saint Vincent de Paul, Paris, France

Copyright

© Belot et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement